Cargando…

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

INTRODUCTION: The thymus is a critical organ for the development of the adaptive immune system and thymic epithelial tumors (TETs; thymomas and thymic carcinomas) are often associated with auto-immune paraneoplastic conditions. However, the immunobiology of TETs is not well described. An evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arbour, Kathryn C., Naidoo, Jarushka, Steele, Keith E., Ni, Ai, Moreira, Andre L., Rekhtman, Natasha, Robbins, Paul B., Karakunnel, Joyson, Rimner, Andreas, Huang, James, Riely, Gregory J., Hellmann, Matthew D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542609/ https://www.ncbi.nlm.nih.gov/pubmed/28771603 http://dx.doi.org/10.1371/journal.pone.0182665

Ejemplares similares

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie, et al.
Publicado: (2014)

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2013)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
por: Kashima, Jumpei, et al.
Publicado: (2022)

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
por: Drilon, Alexander, et al.
Publicado: (2019)

Radiation strategy and techniques for metastatic pleural disease from thymic malignancies: extended abstract
por: Shepherd, Annemarie F., et al.
Publicado: (2022)

Reviewing the role of healthy volunteer studies in drug development
por: Karakunnel, Joyson J., et al.
Publicado: (2018)

Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors
por: Yamamoto, Yoko, et al.
Publicado: (2020)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
por: Cluxton, Christopher, et al.
Publicado: (2023)

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
por: Wang, Luyao, et al.
Publicado: (2023)

Lung neuroendocrine neoplasms: recent progress and persistent challenges
por: Rekhtman, Natasha
Publicado: (2021)

Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma
por: Hasanovic, Adnan, et al.
Publicado: (2011)

Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
por: Wang, Yue, et al.
Publicado: (2018)

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
por: Li, Enliang, et al.
Publicado: (2021)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

A rare case of true thymic hyperplasia in an adult
por: Porter, Angus, et al.
Publicado: (2023)

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
por: Patel, Shabnum, et al.
Publicado: (2019)

Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
por: Mercer, Derry K., et al.
Publicado: (2020)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

Successful Treatment of Scar Pain with Scrambler Therapy
por: Yarchoan, Mark, et al.
Publicado: (2019)

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
por: Wills, Beatriz, et al.
Publicado: (2018)

From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

CytoJounal quiz case: Fine-needle aspiration of peripancreatic mass clinically mimicking a lymphoma
por: Cimic, Adela, et al.
Publicado: (2019)

Lipofibroadenoma and other rare thymic tumors: a call for misfits
por: Planas, Georgina, et al.
Publicado: (2023)

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms
por: Higuchi, Rumi, et al.
Publicado: (2019)

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
por: Zou, Hai, et al.
Publicado: (2022)

Coronavirus Immunotherapeutic Consortium Database
por: Mahita, Jarjapu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qgoqndtu2ftojpdk4cpq0b32p4